Max Grogl is a dedicated and accomplished research and development manager with more than 35 years of diverse experience in biomedical research and development at every level from investigator to senior management during service as a commissioned officer in the US Army Medical Service Corps. His experience includes human and animal use review, clinical trials, partnership negotiations, management and oversight of drugs, vaccines, devices and medical information product development, developing research and cooperative agreements, and planning at the project, program and strategic levels.

He can act as effective interface with scientists and senior leaders in both government and private sector biomedical research, as well as the most senior leadership within the Departments of Army, Navy, Defense, State, Health Human Services and US Congress. He is fluent in multiple languages with effective interface with international organizations and governments. He is a world expert in leishmaniasis, tropical medicine, drug development, manufacturing and Good manufacturing practices (GMP), GCP, ethical conduct and regulations of clinical trials and biosafety and biosurety issues. He has over 150 scientific publications and 12 patents.

Clinical & Regulatory Expert

Over the last 16 years Dr Berman has been working as the Vice President for Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC. Prior to that, Dr Berman had over 20 years experience in clinical and regulatory affairs at large government institutions – Walter Reed Army Institute of Research and the NIH. His main focus has been on the neglected tropical infectious diseases malaria and leishmaniasis. Dr Berman has been the author and/or co-author of over 160 publications. For over 20 years he was a member or chair of WHO Tropical Disease Research committees. Dr Berman was IND director for over a dozen pharmaceuticals and was clinical lead for two submissions/approvals at FDA that obtained a Tropical Disease Priority Review Voucher.

Hans Platteeuw is a highly experienced entrepreneurial product developer with over 25 years of expertise in pharmaceutical drug innovation, with a particular focus on novel treatments for infectious diseases to address global health challenges. Throughout his career, he has played a critical role in translating lead compounds into cost-effective, market-ready pharmaceutical products. Platteeuw is the inventor of over 30 patents across leading companies, including Synthon, Dafra Pharma, Disphar, Mithra, Oxytone Bioscience, and Pamoja Therapeutics. Hans Platteeuw has been a key contributor to the pharmaceutical development of D121. Currently he is the founder and CSO of Galenicap, an innovative company dedicated to the development of improved versions of existing medicines, featuring enhanced efficacy or safety profiles, and potentially offering new therapeutic applications.